Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Latest Breaking News
In reply to the discussion: Antimalarial drug touted by President Trump is linked to increased risk of death in COVID patients [View all]displacedtexan
(15,696 posts)11. Where'd you get the idea it wasn't a controlled study? Here's the actual methodology.
Anecdotal evidence? Where'd you hear that? The source needs to be reported.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext
Methods
We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).
Findings
96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11·1%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·2231·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·3681·531), chloroquine (16·4%; 1·365, 1·2181·531), and chloroquine with a macrolide (22·2%; 1·368, 1·2731·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·9352·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·1065·983), chloroquine (4·3%; 3·561, 2·7604·596), and chloroquine with a macrolide (6·5%; 4·011, 3·3444·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.
We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).
Findings
96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11·1%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·2231·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·3681·531), chloroquine (16·4%; 1·365, 1·2181·531), and chloroquine with a macrolide (22·2%; 1·368, 1·2731·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·9352·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·1065·983), chloroquine (4·3%; 3·561, 2·7604·596), and chloroquine with a macrolide (6·5%; 4·011, 3·3444·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.
Edit history
Please sign in to view edit histories.
15 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
RecommendedHighlight replies with 5 or more recommendations
Antimalarial drug touted by President Trump is linked to increased risk of death in COVID patients [View all]
CousinIT
May 2020
OP
Not to defend the use of the drug, I think it is bogus and I wouldn't take it,
Chainfire
May 2020
#3
Where'd you get the idea it wasn't a controlled study? Here's the actual methodology.
displacedtexan
May 2020
#11